EZH2 and hepatocellular carcinoma: The molecular studies suggested several instances of AR signaling in HCC (summarized in Table 3): upregulating EZH2 expression which correlates with tumor progression and poor prognosis [182]; promoting arachidonic acid metabolism and angiogenic tumor microenvironment in AFP (alpha-fetoprotein)-negative HCC [183]; and serving as a molecular docking target for metformin, resulting in lower AR at protein level and enhanced ferroptosis [180].